Botensilimab: all 30 studies that test it
Page 1 of 1. Open to participants first (15), then studies with results posted, then the rest; newest registration first within each.
- RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal CancerRecruitingNCT07735624Phase 2
- Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3RecruitingNCT07595874Phase 2
- Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat TrialRecruitingNCT07551596Phase 2
- BAL/BOT/agenT-797 in pMMR CRC With Liver MetastasesRecruitingNCT07550088Phase 2
- Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT TrialRecruitingNCT07516366Phase 2
- A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and ChemotherapyRecruitingNCT07227636Phase 2
- Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver MetastasisRecruitingNCT07193862Early Phase 1
- Botensilimab, Balstilimab, and SBRT in Colorectal CancerRecruitingNCT07128355Early Phase 1
- The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-RadiationRecruitingNCT06843551Phase 2
- A Study of Botensilimab and Balstilimab for Rectal AdenocarcinomaRecruitingNCT06843434Phase 2
- FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before SurgeryRecruitingNCT06780787Phase 2
- KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal CancerRecruitingNCT06411691Phase 1
- Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric AdenocarcinomasRecruitingNCT06346197Phase 3
- Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal CancerRecruitingNCT06336902Phase 1
- Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)RecruitingNCT05845450Phase 2
- Combination Immunotherapy in Colorectal CancerCompletedNCT05571293Phase 2Results posted
- Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal AdenocarcinomaTerminatedNCT07152821Phase 3
- Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008)Active, not recruitingNCT06322108Phase 2
- Botensilimab and Balstilimab Optimization in Colorectal CancerActive, not recruitingNCT06268015Phase 2
- A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction CancerActive, not recruitingNCT06251973Phase 2
- The Seven Trial: Exploiting the Unfolded Protein ResponseTerminatedNCT06076837Phase 1
- Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical TrialSuspendedNCT05928806Phase 2
- Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed GlioblastomaActive, not recruitingNCT05864534Phase 2
- Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior ChemotherapyActive, not recruitingNCT05672316Phase 1/2
- A Study of Botensilimab in Participants With Metastatic Pancreatic CancerCompletedNCT05630183Phase 2
- FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal CancerActive, not recruitingNCT05627635Phase 1/2
- A Study of Botensilimab and Balstilimab for the Treatment of Colorectal CancerActive, not recruitingNCT05608044Phase 2
- Study of AGEN1571 in Participants With Advanced Solid TumorsCompletedNCT05377528Phase 1
- Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced CancerCompletedNCT04121676Phase 1
- Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue SarcomasActive, not recruitingNCT04028063Phase 2